Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transtional cell carcinoma of the bladder

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1169-1172

  Menendez López, Violeta ^a,c   Filella, Xavier ^b   Alcover, Juan A ^b   Molina, Ricardo ^b   Mallafre, Josep M ^b   Ballesta, Antonio M ^b   Talbot Wright, Roberto ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Hospital Clinic ^*  (Spain)

Author keywords

Bladder; Carcinoma; NMP22; Nuclear matrix; Nuclear protein; Transitional cell; Urine marker

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECURRENCE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC DISEASES;

EID: 0034053342     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Giella JG, Ring K, Olsson CA, Karp FS and Benson MC: The predictive value of flow cytometry and urinary cytology in tjie follow-up of patients with transitional cell carcinoma of the bladder. J Urol 148: 293-296, 1992.
2. Billery C, Lamy B, Bittard H, Rozam SA and Carbillet JP: Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: Critical review of a 5-year experience. World J Urol 11: 156-160, 1993.
3. Hall RR, Laurence DJR, Darey D, Stevens U, James R, Roberts S, and Munro Neville A: Carcinoembryonic antigen in the urine of patients with urothelial carcinoma. Brit Med J 3: 609-611, 1972.
4. Eraser RA, Ravry MJ, Segura JW and Go VLW: Clinical evaluation of urinary and serum embryonic antigen in bladder cancer. J Urol 114: 226-229, 1975.
5. Sarosdy MF, Devere White RW, Soloway MS, Sheinfeld J, Hudson MA, Scheilhammer PF, Jarowenki MV, Adams G and Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 374-384, 1995.
6. Keesee S, Briggman JB, Thill G and Wu YI: Utilization of nuclear matrix proteins for cancer diagnosis. In: Stein G, ed. Critical Review in eukaryotic gene expression 6: 189-214, 1996.
7. Yang CH, Lambie EJ and Snyder M: NuMA: An unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol 116: 1303-1317, 1992.
8. Compton DA and Cleveland DW: NuMA is required for the proper completion of mitosis. J Cell Biol 120: 847-957, 1993.
9. Miller TE, Beausang LA, Meneghini M and Lidgard GP: Death-induced changes to the nuclear matrix: The use of antinuclear matrix antibodies to study agents of apoptosis. Biotechniques 15: 1042-1047, 1993.
10. Malmstrom PU, Busch C and Norlen BJ: Recurrence, progression and survival in bladder cancer: A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 21: 185-195, 1987.
11. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF and Efird JT: Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329: 1377-1382, 1993.
12. Tetu B, Kak RL, Kalter SP, Von Eschenbach AC and Barlogie B: Flow cytometry of transitional cell carcinoma of the urinary bladder: Influence of prior local therapy. Semin Diagn Pathol 4: 243-250, 1987.
13. Soloway MS, Briggman JV, Carpinit GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Rescrvitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP and Hayden CL: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367, 1996.
14. Botti C, Seregni E, Mattioli S, Martinetti A, Ferrari L and Bombardieri E: Bladder cancer monitoring using two novel urinary markers. Int J Biol Markers 12: 174-180, 1997.
15. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M, Koyama A and Takahashi T: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 31: 163-168, 1997.